Is ESSA Pharma Stock a Good Investment?
ESSA Pharma Investment Advice | EPIX |
- Examine ESSA Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ESSA Pharma's leadership team and their track record. Good management can help ESSA Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact ESSA Pharma's business and its evolving consumer preferences.
- Compare ESSA Pharma's performance and market position to its competitors. Analyze how ESSA Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if ESSA Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ESSA Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in ESSA Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if ESSA Pharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine ESSA Pharma Stock
Researching ESSA Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 71.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.6. Some equities with similar Price to Book (P/B) outperform the market in the long run. ESSA Pharma recorded a loss per share of 0.69. The entity last dividend was issued on the 25th of April 2018. The firm had 1:20 split on the 25th of April 2018.
To determine if ESSA Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ESSA Pharma's research are outlined below:
| ESSA Pharma may become a speculative penny stock | |
| Net Loss for the year was (28.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ESSA Pharma currently holds about 174.6 M in cash with (22.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 71.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Levi Korsinsky Notifies Shareholders of ESSA Pharma Inc. ... |
ESSA Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ESSA Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ESSA Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 10th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact ESSA Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises ESSA Pharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-08 | 2023-06-30 | -0.19 | -0.17 | 0.02 | 10 | ||
2016-02-12 | 2015-12-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2024-02-13 | 2023-12-31 | -0.17 | -0.14 | 0.03 | 17 | ||
2021-11-18 | 2021-09-30 | -0.23 | -0.2 | 0.03 | 13 | ||
2021-02-11 | 2020-12-31 | -0.17 | -0.2 | -0.03 | 17 | ||
2023-05-09 | 2023-03-31 | -0.2 | -0.16 | 0.04 | 20 | ||
2021-08-16 | 2021-06-30 | -0.26 | -0.21 | 0.05 | 19 | ||
2020-08-06 | 2020-06-30 | -0.29 | -0.24 | 0.05 | 17 |
Know ESSA Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ESSA Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ESSA Pharma backward and forwards among themselves. ESSA Pharma's institutional investor refers to the entity that pools money to purchase ESSA Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2024-12-31 | 211.2 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 181.2 K | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 164.6 K | Citadel Advisors Llc | 2024-12-31 | 159 K | Ubs Group Ag | 2024-12-31 | 95.6 K | Two Sigma Advisers, Llc | 2024-12-31 | 82.6 K | Magnus Financial Group Llc | 2024-12-31 | 55.2 K | Vazirani Asset Management Llc | 2024-12-31 | 50 K | Schonfeld Strategic Advisors Llc | 2024-12-31 | 48.8 K | Bvf Inc | 2024-12-31 | 8.7 M | Tang Capital Management Llc | 2024-12-31 | 4.3 M |
ESSA Pharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 71.02 M.Market Cap |
|
ESSA Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.76) | (1.68) | |
| Return On Capital Employed | (1.34) | (1.40) | |
| Return On Assets | (1.21) | (1.15) | |
| Return On Equity | (1.71) | (1.62) |
Determining ESSA Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if ESSA Pharma is a good buy. For example, gross profit margin measures ESSA Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ESSA Pharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in ESSA Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ESSA Pharma. Check ESSA Pharma's Beneish M Score to see the likelihood of ESSA Pharma's management manipulating its earnings.
Evaluate ESSA Pharma's management efficiency
ESSA Pharma has return on total asset (ROA) of (0.1709) % which means that it has lost $0.1709 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2398) %, meaning that it created substantial loss on money invested by shareholders. ESSA Pharma's management efficiency ratios could be used to measure how well ESSA Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1.68 in 2025. Return On Capital Employed is likely to drop to -1.4 in 2025. At this time, ESSA Pharma's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 401 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.78 | 2.02 | |
| Net Current Asset Value | 770.50 | 684.89 | |
| Tangible Asset Value | 770.50 | 684.89 | |
| Tangible Book Value Per Share | 1.17 | 1.87 | |
| Enterprise Value Over EBITDA | (30.04) | (28.54) | |
| Price Book Value Ratio | 49.54 | 52.01 | |
| Enterprise Value Multiple | (30.04) | (28.54) | |
| Price Fair Value | 49.54 | 52.01 | |
| Enterprise Value | 63.9 K | 60.7 K |
The operational strategies employed by ESSA Pharma management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 1.597 |
Basic technical analysis of ESSA Stock
As of the 20th of March, ESSA Pharma shows the Mean Deviation of 1.39, standard deviation of 1.99, and Market Risk Adjusted Performance of 0.4097. ESSA Pharma technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.ESSA Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ESSA Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ESSA Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ESSA Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ESSA Pharma's Outstanding Corporate Bonds
ESSA Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ESSA Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ESSA bonds can be classified according to their maturity, which is the date when ESSA Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand ESSA Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ESSA Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.4097 | |||
| Mean Deviation | 1.39 | |||
| Coefficient Of Variation | (3,119) | |||
| Standard Deviation | 1.99 | |||
| Variance | 3.95 | |||
| Information Ratio | 6.0E-4 | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | 0.0941 | |||
| Treynor Ratio | 0.3997 | |||
| Maximum Drawdown | 13.09 | |||
| Value At Risk | (2.38) | |||
| Potential Upside | 3.23 | |||
| Skewness | 1.42 | |||
| Kurtosis | 4.96 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.4097 | |||
| Mean Deviation | 1.39 | |||
| Coefficient Of Variation | (3,119) | |||
| Standard Deviation | 1.99 | |||
| Variance | 3.95 | |||
| Information Ratio | 6.0E-4 | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | 0.0941 | |||
| Treynor Ratio | 0.3997 | |||
| Maximum Drawdown | 13.09 | |||
| Value At Risk | (2.38) | |||
| Potential Upside | 3.23 | |||
| Skewness | 1.42 | |||
| Kurtosis | 4.96 |
Consider ESSA Pharma's intraday indicators
ESSA Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ESSA Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ESSA Pharma time-series forecasting models is one of many ESSA Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ESSA Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ESSA Stock media impact
Far too much social signal, news, headlines, and media speculation about ESSA Pharma that are available to investors today. That information is available publicly through ESSA media outlets and privately through word of mouth or via ESSA internal channels. However, regardless of the origin, that massive amount of ESSA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ESSA Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ESSA Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ESSA Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ESSA Pharma alpha.
ESSA Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards ESSA Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ESSA Pharma Historical Investor Sentiment
Investor biases related to ESSA Pharma's public news can be used to forecast risks associated with an investment in ESSA. The trend in average sentiment can be used to explain how an investor holding ESSA can time the market purely based on public headlines and social activities around ESSA Pharma. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ESSA Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ESSA Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average ESSA Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on ESSA Pharma.
ESSA Pharma Corporate Management
| Erin Rudsinski | Executive | Profile | |
| CMA CPA | Chief Officer | Profile | |
| Terry Schuenemeyer | Executive | Profile | |
| Neil Thapar | Executive | Profile | |
| Nkengyal Barber | Executive | Profile | |
| Alessandra MD | Chief Officer | Profile |
Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.